Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11416)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Dec 9, 2014 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Pharmacology
ISSN
2220-3192
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Starosyla SA, Volynets GP, Bdzhola VG, Golub AG, Yarmoluk SM. Pharmacophore approaches in protein kinase inhibitors design. World J Pharmacol 2014; 3(4): 162-173 [DOI: 10.5497/wjp.v3.i4.162] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v3/i4/162.htm |
| Number | Citing Articles |
| 1 |
Khaled El‐Adl, Helmy Sakr, Mohamed Nasser, Mohamed Alswah, Fatma M. A. Shoman. 5‐(4‐Methoxybenzylidene)thiazolidine‐2,4‐dione‐derived VEGFR‐2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations. Archiv der Pharmazie 2020; 353(9) doi: 10.1002/ardp.202000079
|
| 2 |
Domiziana Masci, Charlotte Hind, Mohammad K. Islam, Anita Toscani, Melanie Clifford, Antonio Coluccia, Irene Conforti, Meir Touitou, Siham Memdouh, Xumin Wei, Giuseppe La Regina, Romano Silvestri, J. Mark Sutton, Daniele Castagnolo. Switching on the activity of 1,5-diaryl-pyrrole derivatives against drug-resistant ESKAPE bacteria: Structure-activity relationships and mode of action studies. European Journal of Medicinal Chemistry 2019; 178: 500 doi: 10.1016/j.ejmech.2019.05.087
|
| 3 |
Khaled El‐Adl, Abdel‐Ghany A. El‐Helby, Helmy Sakr, Sanadelaslam S. A. El‐Hddad. Design, synthesis, molecular docking, and anticancer evaluations of 1‐benzylquinazoline‐2,4(1H,3H)‐dione bearing different moieties as VEGFR‐2 inhibitors. Archiv der Pharmazie 2020; 353(8) doi: 10.1002/ardp.202000068
|
| 4 |
Khaled El‐Adl, Mohamed‐Kamal Ibrahim, Fathalla Khedr, Hamada S. Abulkhair, Ibrahim H. Eissa. N‐Substituted‐4‐phenylphthalazin‐1‐amine‐derived VEGFR‐2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies. Archiv der Pharmazie 2021; 354(3) doi: 10.1002/ardp.202000219
|
| 5 |
Mohamed M. Saleh, Tarek El-Moselhy, Eman El-Bastawissy, Mahmoud A.A. Ibrahim, Shaban R.M. Sayed, Mohamed-Elamir F. Hegazy, Thomas Efferth, Laila A. Jaragh-Alhadad, Peter A. Sidhom. The mystery of titan hunter: Rationalized striking of the MAPK pathway via Newly synthesized 6‐Indolylpyridone‐3‐Carbonitrile derivatives. European Journal of Medicinal Chemistry 2023; 259: 115675 doi: 10.1016/j.ejmech.2023.115675
|
| 6 |
Mykola V. Protopopov, Olga V. Ostrynska, Sergiy A. Starosyla, Maria A. Vodolazhenko, Svetlana M. Sirko, Nikolay Yu. Gorobets, Volodymyr Bdzhola, Sergey M. Desenko, Sergiy M. Yarmoluk. Dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-4-ones as a new class of CK2 inhibitors. Molecular Diversity 2018; 22(4): 991 doi: 10.1007/s11030-018-9836-1
|